Cobicistat / darunavir / emtricitabine / tenofovir alafenamide and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with cobicistat / darunavir / emtricitabine / tenofovir alafenamide which include:
Moderate Food Interaction
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: Food enhances the absorption and oral bioavailability of darunavir administered in combination with low-dose ritonavir. The mechanism is unknown. When administered with food, the peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of darunavir were approximately 30% higher than when administered in the fasting state. Darunavir exposure was similar for the range of meals studied. The total caloric content of the various meals evaluated ranged from 240 Kcal (12 grams fat) to 928 Kcal (56 grams fat).
MANAGEMENT: To ensure maximal oral absorption, darunavir coadministered with ritonavir should be taken with food. The type of food is not important.
- "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.
Minor Food Interaction
Information for this minor interaction is available on the professional version.
Cobicistat / darunavir / emtricitabine / tenofovir alafenamide drug interactions
There are 656 drug interactions with cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Cobicistat / darunavir / emtricitabine / tenofovir alafenamide disease interactions
There are 11 disease interactions with cobicistat / darunavir / emtricitabine / tenofovir alafenamide which include:
- hepatitis B
- renal dysfunction
- creatinine clearance
- renal dysfunction
- bone toxicity
- liver disease
More about cobicistat / darunavir / emtricitabine / tenofovir alafenamide
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 2 Reviews
- Drug class: antiviral combinations
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|